Nonclinical Toxicology 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2-year carcinogenicity study in CD-1 mice, subcutaneous doses of 0.3, 1 and 3 mg/kg/day [2-, 11-, and 30-fold the maximum recommended human dose (MRHD) of 2 mg/week, based on AUC] were administered to the males, and 0.1, 0.3 and 1 mg/kg/day (1-, 2-, and 7-fold MRHD) were administered to the females
You may have even seen advertisements promoting medicines that accelerate weight loss
KE received honoraria for speaking at meetings from Novartis, Sanofi Aventis, Eli Lilly and Company, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk
We attribute this phenomenon to the speculation that L
MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis